Diskusjon Triggere Porteføljer Aksjonærlister

Follicum

Spennende selskap med peptid for økt hårvekst på hodet med en topikal-formulering og diabetes (frigjøring av insulin).

"Follicum became a partner in a large research project on diabetes during 2017

The Swedish Foundation for Strategic Research is funding different projects in life science and technology. Follicum was invited to participate in a diabetes project, headed by the University of Lund (LUDC-IRC). The funding is 100 MSEK (roughly 12 MUSD) over several years. Follicum is partnering with several large, commercial players in the project, like Novo Nordisk, Johnson & Johnson Innovation, Pfizer and others as well as the Region Skåne through the University Hospital of Malmö.

Our early work with the peptide FOL-014 has been noted by the Novo Nordisk Foundation. The foundation has granted 400 KDKK (roughly 45 KUSD) for continued pre-clinical trials and development of FOL-014."

1 Like

Grei dag og utvikling så langt :slight_smile: Ikke værst å itillegg få valuta-gevinst i samme slengen :slight_smile:

Jeg tok en liten lyttepost i emisjonen ( uten tegningsretter ) men angrer jo selvfølgelig på at jeg ikke tok mer :wink:

1 Like

Jeg deltok også i emisjonen og søkte om en del tusen t-retter ekstra og fikk en del. Aldri vært så høy omsetning som idag i Folli :muscle::blush: Deltok i emisjonen ifjord også. Ble en fin reise :blush: men ventet litt for lenge med å selge.

1 Like
1 Like

Kommer denne endelig for fullt nå? :grin:

Ja det var deilig å få den på plass, men vi venter enda på denne:

“Resultat för effekter av peptidklassen på diabeteskomplikationer – H2 2019”

Spennende dager!

Da fikk insulin-release. Kan vi få enda et før jul om komplikasjoner? Jan har vel også til vane å komme med en “julehilsen”.

Follicum annnouces positive human ex vivo data from preclinical diabetes studies of new class of FOL peptides


Follicum

17.12.2019, 08:39·Cision

Follicum AB (“Follicum” or “the Company”) today announces that data from studies on human Langerhans islets have shown positive effects on insulin release in line with the previously reported results on beta cells isolated from animals. The studies were performed through two different collaborations, one with Lund University and one with InSphero, Switzerland and showed similar results.

The Company’s development of a peptide-based treatment of diabetes and its complications is proceeding according to plan. Follicum has studied the ability of peptides to induce insulin secretion in Langerhans islets derived from human donors. The studies show that in these ex vivo studies the peptides has the ability to release insulin in line with a GLP-1 analogue. Thus the effect of the peptides on beta cell lines previously reported can be reproduced in human material.

These studies are two of several studies that is presently ongoing to further substantiate the therapeutic value of FOL-peptides in various diabetic complications.

CEO Jan Alenfall comments

  • We are very pleased to be able to report these findings from two different labs. It is important to report effects in human material at an early stage. The results of these studies show that Follicum’s peptides are as potent as a GLP-1 analogue in human material.

About Diabetes

Diabetes is rapidly increasing globally. The disease is characterized by poor blood sugar control due to defective insulin signalling, which causes serious sequelae such as cardiovascular disease, renal failure, obesity, blindness and diabetic foot ulcers. Diabetes as well as its accompanying illnesses represent a major burden, partly for the individual patient, but also for the entire health care system. There is thus an already large and growing global need for new therapies that address effective control of glucose levels in combination with preventive effects on the various diabetic complications.

For further information, please contact:

Jan Alenfall - CEO, Follicum AB

1 Like

Kommer denne endelig for fullt nå? :slight_smile:

1 Like

Snart resultater :crossed_fingers: :crossed_fingers:

Sur dag. Biotek er risky uansett hvor bra det ser ut.

Tenker tiden er inne for å legge biotek på hylla og flytte over resten av pengene også til krypto :grin::rocket:

2 Likes